HKH40A downregulates GRP78/BiP expression in cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Solid tumors often exhibit elevated GRP78/BiP, a protein crucial for cancer cell survival and chemoresistance.
• The molecular mechanisms of synthetic antitumor agents like HKH40A are not fully understood.
• GRP78/BiP is a potential therapeutic target for cancer treatment.

Purpose of the Study:

• To elucidate the molecular mechanisms by which HKH40A exerts its antitumor effects.
• To investigate the role of GRP78/BiP in HKH40A's anticancer activity.
• To evaluate the therapeutic potential of HKH40A in preclinical cancer models.

Main Methods:

• Assessing HKH40A's effect on GRP78/BiP protein levels in various cancer cell lines.
• Investigating HKH40A's impact on GRP78 gene transcription and protein degradation.
• Utilizing gene knockdown and overexpression techniques to study BiP's role.
• Analyzing the unfolded protein response (UPR) pathways (IRE1α, ATF6, PERK) and downstream signaling.
• Evaluating HKH40A's efficacy in an in vivo xenograft tumor model.

Main Results:

• HKH40A significantly reduces GRP78/BiP protein levels in diverse cancer cell lines.
• HKH40A downregulates GRP78 transcription and promotes proteasomal degradation of the protein.
• BiP knockdown enhances HKH40A efficacy, while BiP overexpression diminishes it.
• HKH40A treatment activates the UPR, leading to downstream signaling events including eIF2α phosphorylation and ATF4/CHOP upregulation.
• HKH40A demonstrated significant inhibition of tumor formation in vivo.

Conclusions:

• HKH40A's antitumor activity is mediated, in part, by the reduction of GRP78/BiP levels.
• Targeting GRP78/BiP with HKH40A represents a promising therapeutic strategy against solid tumors.
• The induction of UPR by HKH40A contributes to its anticancer effects.